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Introduction
Sickle cell disease (SCD) is characterized by multi-organ morbidity and an
increased risk of early death. Several studies show that the survival of children with
SCD has improved over the last decades.1 This improved survival is attributed to
the implementation of newborn screening, use of prophylactic penicillin, and vac-
cinations against Haemophilus influenza type b and Streptococcus pneumonia,2-4 with
possible contributions from advances in red blood cell transfusion medicine, iron
chelation therapy, and transcranial Doppler screening to identify those at increased
risk of stroke.5,6
The Cooperative Study of Sickle Cell Disease (CSSCD), a multicenter natural his-
tory study of SCD conducted between 1978 and 1988, reported median ages at
death during the study period of 42 and 48 years, respectively, for male and female
HbSS patients, and median ages at death of 60 and 68 years, respectively, for male
and female HbSC patients.7 While many patients died following acute episodes of
pain, acute chest syndrome or stroke, statistical modeling revealed that the acute
chest syndrome, renal failure, seizures, high white blood cell count (WBC) and low
level of fetal hemoglobin (HbF) were associated with an increased risk of early
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ABSTRACT
death in HbSS patients.7 However, this prospective study
was conducted prior to the approval of hydroxyurea for
the treatment of sickle cell anemia. More recent studies
show associations of elevated echocardiography-derived
tricuspid regurgitant jet velocity (TRV),8,9 pulmonary
hypertension (PHT),10,11 elevated levels of N-terminal pro-
brain natriuretic peptide (NT-pro-BNP),12 history of asth-
ma and/or wheezing,13 end-stage renal disease requiring
dialysis,14 severity of hemolysis,15 and prolongation of QTc
interval16 with an increased risk of death in patients with
SCD. 
Hydroxyurea, approved by the US Food and Drug
Administration (FDA) in 1998, remains the only drug that
has been shown to alter the natural history of SCD in
peer-reviewed studies. In two randomized, placebo-con-
trolled studies, hydroxyurea was shown to decrease the
frequency of acute pain episodes, acute chest syndrome,
red blood cell (RBC) transfusion and hospitalization rates
in both adults and children with sickle cell anemia.17,18
Despite the studies showing an improved survival in adult
patients with SCD following treatment with hydrox-
yurea,19-21 the mortality rate remains high for patients aged
18 years or older following transition to adult care,22 pos-
sibly reflecting a lack of access to high-quality care. The
present study evaluated the association of selected clinical
and laboratory variables with mortality in a cohort of
adult patients with SCD followed at an academic medical
center. With the relatively small number of patients evalu-
ated in this single center study, we have conducted com-
prehensive meta-analyses of contemporary prospective
and retrospective studies to evaluate the factors associated
with mortality in adult patients with SCD following the
approval of hydroxyurea. Our goal is to uncover the
underlying causes of mortality in SCD.
Methods
Patients and study design
We evaluated a subset of patients followed at the
Comprehensive Sickle Cell Clinic at the University of North
Carolina (UNC), Chapel Hill between August 2004 and December
2014 (subsequently referred to as the UNC cohort).  The data were
collected as part of a prospective study of the natural history of
pulmonary hypertension in SCD.9 The patients were evaluated
while in a non-crisis, 'steady state'; they had not experienced an
episode of acute chest syndrome in the four weeks preceding
enrollment, and had no clinical evidence of congestive heart fail-
ure. This study was approved by the Institutional Review Board at
UNC, Chapel Hill, and all subjects gave written informed consent
to participate in accordance with the Declaration of Helsinki.
Sickle cell disease-related clinical complications and
laboratory variables
The presence or history of clinical complications, including the
number of acute pain episodes (or vaso-occlusive crises) in the past
year, history of acute chest syndrome, and use of hydroxyurea,
was ascertained at the time of evaluation as well as through a
review of the patients’ medical records.  Acute pain episodes,
acute chest syndrome, and other SCD-related complications were
defined using accepted definitions.19,23 SCD genotypes were
dichotomized into clinically severe (HbSS, HbSβ0 thalassemia and
HbSD) and less severe (HbSC and HbSβ+ thalassemia) groups. The
TRV was measured by continuous wave Doppler echocardiogra-
phy. Multiple views were obtained to record optimal tricuspid
flow signals. Measurements were performed on at least three
waveforms with well-defined velocity envelopes and an average
value was used for data analysis. Patients with non-quantifiable
TRVs were assumed to have normal estimated PASP. The echocar-
diograms were interpreted by a cardiologist blinded to all patient
data. 
Laboratory measurements obtained in study subjects include
complete blood counts with reticulocyte counts, serum creatinine,
lactate dehydrogenase, total bilirubin, direct bilirubin, indirect
bilirubin, D-dimer and NT-pro-BNP. Hemoglobin analysis was
performed by high performance liquid chromatography to con-
firm the SCD diagnosis and ascertain HbF levels.
Search strategy and covariate abstraction
A meta-analysis was conducted in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines and Meta-Analysis of Observational Studies
in Epidemiology Group criteria.24 Published articles were identified
using MEDLINE (PubMed), Web of Science and EMBASE search
engines between January 1, 1998, and June 30, 2016. The search
on PubMed was performed using the Medical Subject Headings
(MeSH) “anemia, sickle cell [mesh] OR “sickle cell disease” OR
"sickle cell anemia" AND “mortality OR survival.”  The search on
Web of Science was performed using the search terms “sickle cell”
AND “mortality OR survival” and the search on EMBASE was per-
formed using the search terms “sickle cell anemia OR sickle cell
disease” AND “mortality OR survival”. In addition, we interrogat-
ed references from relevant original papers and review articles to
identify further relevant studies. Reviews, editorials, duplicate
citations, non-human studies, highly selected study populations,
retrospective analyses of large administrative datasets and articles
written in languages other than English were excluded. We limited
our analysis to prospective and retrospective studies conducted in
North America and Europe and published since 1998, the year
hydroxyurea was approved by the FDA for treatment of sickle cell
anemia. Multiple publications from the same patient population
were narrowed down to the single publication with the most
complete information. Eligible studies were combined with the
UNC cohort for meta-analyses.
Statistical analysis
Median, range and interquartile range for continuous variables
and frequencies for categorical variables were provided in the
UNC cohort. NT-pro-BNP was log-transformed based on previous
literature.25 We evaluated the Spearman correlation coefficient of
each pair of variables to check the collinearity. Median ages at
death were calculated for those individuals who died during the
study. Median survival age was calculated based on Kaplan-Meier
estimates for the survival probability using age as the time scale
taking into account the left truncation. Log-rank tests were con-
ducted to compare survival probabilities among different groups.
Cox proportional hazards regression was fit to the data and vari-
ables were selected by backward elimination at 5% level of signif-
icance to obtain the final model. Schoenfeld residuals were used to
check the proportional hazards assumption.  Hazard ratios (HRs)
were calculated in the UNC cohort, controlling for age and sex. 
Mortality HRs were meta-analyzed using DerSimonian and
Laird26 random effects models26,27 due to the diversity of individual
studies and the small number of studies included. The Knapp and
Hartung27 method was used to adjust the standard errors of the
estimated coefficients. Unadjusted HRs in the studies were used
for our meta-analyses whenever they were reported. The degree
of heterogeneity across the studies was examined using I2 values,28
classifying more than 50% as moderate heterogeneity, and more
than 75% as high heterogeneity. Meta-analysis was performed if
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HRs were available from a minimum of 3 studies. We considered
the Voskaridou et al. study21 to contribute two separate HRs
depending on whether patients received hydroxyurea. Similarly,
from the Elmariah et al. study,25 two estimates were used based on
the use of hydroxyurea. All the analyses were performed using
SAS statistical software v.9.4 (Cary, NC, USA). The graphs for the
meta-analyses were made using the R Project for Statistical
Computing.
Results
Study population 
One hundred and sixty-one subjects in the UNC cohort
[female: 97 (60.3%)] with SCD (SS: 119; SC 19; Sβ0: 12;
Sβ+: 10; SD: 1), and a median age of 36 years (range 18-71
years) (Table 1) were followed for a median duration of
7.2 years (range 0.06-10.3 years) and a total of 954.0 per-
son-years.  The majority of the subjects [159 (99%)] were
self-reported African Americans. There were 29 (18%)
deaths during the period of follow up (SS: 20, SC: 4, Sβ0: 3,
Sβ+: 2). Amongst those who died during the study, the
median age of death was 48.0 years (range 29.8-70.2
years), while the median age in the  subjects alive at the
time of last contact was 38.7 years (range 22.6-79.4 years).
When the subjects were grouped based on presumed dis-
ease severity (SS/Sβ0/SD vs. SC/Sβ+), the median age at the
time of death in the SS/Sβ0/SD group was 44.7 years
(range 24.1-79.4 years), while the median age at the time
of death in the SC/Sβ+ group was 59.4 years (range 29.8-
69.2 years). The median survival age for all subjects in the
UNC cohort was 50.2 years [95% confidence interval (CI):
45.2-62.3 years) (Figure 1), with a median survival age in
the SS/Sβ0/SD group of 49.0 years (95%CI: 44.9-68.6
years). With the small total number of subjects and
deceased subjects in the SC/Sβ+ group, the median survival
age in this group cannot be reliably estimated.
Factors associated with mortality in UNC cohort
Deaths in the UNC cohort were ascertained from hospi-
tal records as well as vital statistics data from the North
Carolina Center for Health Statistics. The variables in the
initial model are shown in Table 2. When covariates were
grouped based on quartiles, age (P=0.036), TRV (P=0.012),
hemoglobin (P=0.018), creatinine (P=0.047) and log(NT-
pro-BNP) (P=0.0022) were associated with an increased
risk of death (Figure 2A-E) in univariate analysis of a sub-
set in this cohort (SS/Sβ0/SD group). There were no asso-
ciations between WBC, platelet count, reticulocyte count,
HbF, lactate dehydrogenase, the number of acute pain
episodes in the previous year, history of acute chest syn-
drome, or hemoglobin genotype with mortality in univari-
ate analysis of patients in the SS/Sβ0/SD group.
Multivariable analysis
We found that the correlation coefficient between each
pair of variables was less than 0.6 and, hence, the variables
are not collinear (Online Supplementary Table S1). Carrying
out the usual backward variable selection, TRV [hazard
ratio (HR): 22.7, 95%CI: 5.88-87.5; P<0.0001], frequency of
acute pain episodes in the previous year (HR: 1.2, 95%CI:
1.06-1.35; P=0.0038) and D-dimer (HR: 1.24 for 1000 ng/mL
increment in D-dimer, 95%CI: 1.07-1.44; P=0.0039) were
Table 1. Baseline demographic and laboratory characteristics of UNC cohort.
Characteristic Number Number (%)/median 
(interquartile range)
Age (years) 161 36 (27-44)
Sex 161
Male 64 (40%)
Female 97 (60%)
Race 161
Black 159 (99%)
Hispanic 2 (1%)
Genotype 161
SS 119 (73.9%)
Sβ0 12 (7.5%)
Sβ+ 10 (6.2%)
SC 19 (11.8%)
Other (SD) 1 (0.6%)
Use of hydroxyurea 161
Yes 93 (58%)
No 68 (42%)
White blood cell count (x109/L) 161 9.3 (7.2-11.2)
Hemoglobin (g/dL) 161 8.9 (7.9-10.3)
Platelet count (x109/L) 159 408 (303-498)
Reticulocyte count (%) 159 6.3 (4.3-9.2)
Absolute reticulocyte count 158 176.35 (125.4-241.6)
Fetal hemoglobin (%) 158 5.6 (2.6-10.7)
Creatinine (mg/dL) 161 0.7 (0.6-0.9)
Lactate dehydrogenase (U/L) 158 847.5 (644-1136)
Total bilirubin (mg/dL) 161 1.9(1.1-3.0)
Indirect bilirubin (mg/dL) 158 1.8(1.1-2.7)
Direct bilirubin (mg/dL) 158 0.1(0.09-.1)
D-dimer (ng/mL) 121 1234 (740-2023.3)
Tricuspid regurgitant 110 2.4(2.16-2.8)
jet velocity (m/s)
Number of pain episodes 161 3 (1-5)
in previous year
History of acute chest syndrome 161
Yes 135(84%) 
No 26(16%)  
Figure 1. Kaplan-Meier survival curves for all subjects and subjects in the
SS/Sβ0/SD group in the UNC Cohort. The median age of survival for all subjects
was 50.2 years (95%CI: 45.2–62.3 years). The median age of survival of sub-
jects in the SS/Sβ0/SD group was 49.0 years (95%CI: 44.9–68.6 years).
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found to be associated with an increased risk of death. The
HR estimates indicate that after controlling for the other
variables, the hazard of dying was approximately 23 times
higher for every 1 m/s increase in the TRV; for each addi-
tional pain episode requiring an emergency department
visit or hospitalization, the hazard of dying was increased
by 20%, and the hazard of dying was approximately 1.24
times higher for every 1000 ng/mL increase in the D-dimer.
When a sensitivity analysis was performed with an
assigned TRV value of 1.69 m/s (lower than the lowest
measurable TRV value in the cohort) for all missing values,
TRV was no longer significantly associated with an
increased risk of death.  When D-dimer was excluded from
the model due to missing values in some subjects, age (HR:
1.04, 95%CI: 1.009-1.073; P=0.012), reticulocyte count (HR:
1.09, 95%CI: 1.015-1.17; P=0.018) and log(NT-pro-BT) (HR:
1.62, 95%CI: 1.21-2.17; P=0.001) were associated with an
increased risk of death.  
Meta-analysis
Our initial search retrieved 1490 articles from PubMed,
1668 articles from Web of Science and 2444 articles from
EMBASE (Figure 3). Nine studies11,21,24,29-34 met our inclu-
sion criteria and were analyzed together with the UNC
cohort for a total of 3257 participants. The quality of
individual studies was assessed using the Newcastle-
Ottawa Scale (Table 3). We were unable to evaluate pub-
lication bias due to the small number of studies included
in the meta-analysis.35 Because the Walk-PHaSST cohort31
included patients as young as 12 years old, we restricted
our analyses to only those patients who were at least 18
years old. The number of patients in the meta-analyses
of the selected variables are shown in Table 3. The num-
ber of studies included in the meta-analyses varied from
3 to 9 depending on what had been reported for each
variable in the publications. The median age of death of
deceased subjects in these studies (available in only 5 of
the 9 published studies) ranged between 39.7 and 53
years. The median age of survival for the subjects with
severe SCD genotypes (SS/Sβ0/SD), available in only 3
studies (2 of the published 9 studies plus the UNC
cohort), ranged between 49.0 and 60.8 years. We found
statistically significant associations of age (per 10-year
increase in age) (HR: 1.28; 95%CI: 1.10-1.50), TRV  2.5
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Table 2. Univariate and multivariate Cox proportional hazards regression analysis of mortality for demographic, laboratory and clinical variables
in the UNC cohort.
Covariate Total number Number of Hazard Ratio Hazard Ratio Hazard Ratio
of patients deceased patients (95% CI)a (95% CI)b (95% CI)c
Age (per 10 years) 161 29 1.59 (1.21-2.09) 1.59 (1.21-2.09)
+Sex 
Male vs. female 161 29 0.83 (0.39-1.79) 0.85 (0.40-1.83)
+Genotype 161 1.12 (0.44-2.81) 0.83 (0.34-2.03)
SS/Sβ0/SD 23
SC/Sβ+ 6
+Use of hydroxyurea 161 (29) 0.592 (0.28-1.25) 0.51 (0.25-1.08)
Yes 12
No 17
+Acute chest syndrome 161 (29) 1.50 (0.51-4.42) 1.15 (0.40-3.31)
Yes 25
No 4
+Tricuspid regurgitant jet velocity   110 (17) 2.79 (0.88-8.84) 3.82 (1.24-11.75)
(dichotomized)
≥2.5 m/s 13
<2.5 m/s) 4
Tricuspid regurgitant jet velocity 110 17 4.98 (1.65-15.02) 6.26 (2.50-15.63) 22.7 (5.88-87.5)
(continuous)
Number of pain episodes in previous year 161 29 1.096 (1.01-1.2) 1.05 (0.97-1.15) 1.20 (1.06-1.35)
White blood cell count 161 29 1.11 (0.97-1.27) 1.05 (0.92-1.19)
Hemoglobin 161 29 0.72 (0.57-0.9) 0.72 (0.57-0.90)
Platelet count 159 29 1.002 (0.99-1.01) 1.000 (0.998-1.003) 
Absolute reticulocyte count 158 28 1.002 (1.00-1.01) 1.001 (0.999-1.004)
Fetal hemoglobin 158 29 0.952 (0.9-1.01) 0.95 (0.89-1.01)
Creatinine 161 29 1.67 (1.04- 2.67) 1.744 (1.14-2.67)
Reticulocyte count (%) 159 29 1.1 (1.02-1.18) 1.05 (0.98-1.12)
Lactate dehydrogenase 158 29 1.00 (0.99-1.0) 1.00 (1.000-1.001)
Total bilirubin 161 29 1.06 (0.88-1.27) 0.97 (0.81-1.16)
D-dimer (per 1000 ng/mL) 121 26 1.11 (1.001-1.22) 1.083 (0.99-1.19) 1.24 (1.07-1.44)
Log(NT-pro-BNP) 158 28 1.59 (1.22-2.08) 1.77 (1.39-2.25)
Ferritin 84 8 1.001 (1.0-1.0) 1.00 (1.000-1.001)
aHazard ratio adjusted for age and sex; bhazard ratio based on the univariable model; chazard ratio based on the multivariable model. +Dichotomized variables.
m/s or more (HR: 3.03; 95%CI: 2.0-4.60), reticulocyte
count (HR: 1.05; 95%CI: 1.01-1.10), HbF (HR: 0.97;
95%CI: 0.94-1.00), and log(NT-pro-BNP) (HR: 1.68;
95%CI: 1.48-1.90) with mortality (Figure 4A-E). This
means that the weighted hazard of dying was approxi-
mately 30% higher for every 10-year increase in age,
approximately 200% higher for TRV  2.5 m/s or more
compared to lower values, approximately 5% higher for
every 1% increase in reticulocyte count; approximately
3% lower for every 1% increase in HbF, and approxi-
mately 100% higher for every 1 unit increase in log(NT-
pro-BNP).
No statistically significant associations were found
between WBC (HR: 1.05; 95%CI: 0.97-1.14), hemoglobin
(HR: 0.86; 95%CI: 0.68-1.09), platelet count (HR: 1.00;
95%CI: 1.00-1.00), ferritin (HR: 1.00; 95%CI: 0.99-1.01),
creatinine (HR: 1.20; 95%CI: 0.95-1.52),  lactate dehydro-
genase (HR: 1.00; 95%CI: 1.00-1.00), total bilirubin (HR:
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Figure 2. Kaplan-Meier survival curves for variables (grouped as quartiles)
associated with increased mortality on univariate analysis in the UNC Cohort.
(A) Increased age is significantly associated with mortality (log-rank test statis-
tic: 8.53; P=0.036). (B) Increased tricuspid regurgitant jet velocity (TRV) is asso-
ciated with mortality (log-rank test statistic: 10.93; P=0.012). (C) Decreased
hemoglobin is significantly associated with mortality (log-rank test statistic:
10.12; P=0.018). (D) Increased creatinine is significantly associated with mor-
tality (log-rank test statistic: 7.95; P=0.047). (E) Increased log(NT-pro-BNP) is
associated with mortality (log-rank test statistic: 14.6; P=0.0022).
A B
C D
E
1.08; 95%CI: 0.93-1.25), use of hydroxyurea (HR: 0.70;
95%CI: 0.41-1.22), history of acute chest syndrome (HR:
1.14; 95%CI: 0.50-2.59), and male sex (HR: 1.47; 95%CI:
0.41-5.31) with mortality (Online Supplementary Figure
S1A-J).  
All of the studies, except that of Karacaoglu et al.,34 used
the time from entry to event as the response variable. We
performed a sensitivity analysis by removing this study
from the meta-analysis. The results are similar [with and
without: WBC 1.05 (0.97, 1.14) vs. 1.03 (0.93, 1.14); hemo-
globin 0.87 (0.61, 1.25) vs. 0.92 (0.62, 1.36); and HbF 0.97
(0.94, 1.00) vs. 0.97 (0.94, 1.00)]. The study was, therefore,
maintained in the meta-analysis.
Discussion
As patients with SCD age, they begin to manifest evi-
dence of end-organ damage which contributes to
increased morbidity and early mortality. In random effects
meta-analyses, we find statistically significant associations
of increased reticulocyte count, TRV and log(NT-pro-BNP)
with increased mortality, whereas decreased HbF was
associated with increased mortality. While no significant
associations were seen between either hemoglobin or lac-
tate dehydrogenase and the risk of death, the association
of increased reticulocyte count with mortality suggests
that hemolysis may contribute to the increased mortality
observed in SCD. The intensity of hemolytic anemia, eval-
uated using a composite variable derived from several
individual markers of hemolysis (reticulocyte count,
serum lactate dehydrogenase, aspartate aminotransferase
and total bilirubin concentrations), was associated with an
increased risk of death in a previous study of patients with
SCD.15 Hemolysis with the subsequent release of cell-free
hemoglobin results in the generation of reactive oxygen
species which is a potent scavenger of nitric oxide.36 This
appears to predispose patients to a vasculopathy, charac-
terized by systemic and pulmonary hypertension,
endothelial dysfunction, and proliferative changes in the
intima and smooth muscle of blood vessels.37 In addition
to their relationship with hemolysis, reticulocytes are
more adhesive than mature erythrocytes due to increased
expression of the integrin complex, α4β1 (which binds to
both fibronectin and vascular cell adhesion molecule-1, an
adhesion receptor expressed on the surface of endothelial
cells) as well as expression of CD36 by a subpopulation of
sickle reticulocytes.38 The degree of adhesiveness is report-
edly correlated with the severity of disease in patients
with SCD.39
We further confirm the association of both elevated
echocardiography-derived TRV and NT-pro-BNP levels
with increased mortality in adult SCD patients. As
increased TRV is not sufficiently specific to confidently
establish the presence of PHT,10 a right heart catheteriza-
tion (RHC) is required in patients with elevated TRV val-
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Figure 3. Search strategy and results. Our analysis was limited to studies conducted
in North America and Europe and published between January 1, 1998 and June 30,
2016.
Table 3. Summary of publications in meta-analysis.
Publication # of Sickle cell Variable with Hazard Ratio Median/mean age Median age Duration of Quality
subjects disease genotypes at death of deceased of survival follow up appraisal
subjects (years) of SS/Sβ0/SD (Newcastle-
subjects Ottawa Scale
(years) [NOS])
*Voskaridou et al., 201021 131 HbSS, HbSβ0, HbSβ+ Age (Median: 33.0, SD: 11.2, HR: 0.99; N/A N/A 5 years 6
0.94-1.05) (range: 0.1-18)
LDH (Mean: 753.88, SD: 413.62, HR: 0.99; 
0.99-1.0)
Reticulocyte count (%) (Mean: 10.03, 
SD: 7.32, HR: 1.01; 0.94-1.09)
Hemoglobin (Mean: 9.10, SD: 1.39, 
HR: 0.88; 0.60-1.3)
HbF (Mean: 7.09, SD: 5.26, HR: 0.95; 
0.82-1.09)
Bilirubin (Mean: 1.92, SD: 3.27, 
HR : 1.09; 0.99-1.2)
**Voskaridou et al., 201021 199 HbSS, HbSβ0, HbSβ+ Age (Median: 35.0, SD: 12.8, N/A N/A 8 years 6
HR: 0.98; 0.93-1.04) (range: 0.1-17)
LDH (Mean: 701.16, SD: 330.16, 
HR: 1.0; 1.0-1.0)
Reticulocyte count (%) (Mean: 6.88, 
SD: 6.38, HR: 1.06; 1.02-1.09)
Hemoglobin (Mean: 9.43, SD: 1.67, 
HR: 0.74; 0.62-0.89)
HbF (Mean: 5.58, SD: 6.22, HR: 0.92; 0.86-0.99)
Bilirubin (Mean: 1.80, SD: 1.61, HR: 1.31; 1.16-1.49)
Saraf et al., 201129 306 HbSS, HbSβ0 Age (HR: 1.03; 1.0-1.05) N/A N/A 1/1/1997 - 8
Creatinine (HR: 1.14; 0.99-1.3) 6/30/2009
HbF (HR: 0.99; 0.95-1.04)
WBC (HR: 0.94; 0.87-1.01)
Mehari et al., 201311 84 HbSS, HbSC, HbSβ0, Age (HR: 1.0; 0.97-1.03) N/A N/A 4.7 years 6
HbSβ+, other Creatinine (HR: 1.09; 0.71-1.67) (maximum 
genotypes not defined Ferritin (HR: 1.26; 1.04-1.53) follow up of 11 years)
Cabrita et al., 201332 164 HbSS, HbSC, HbSβ0, Age (Median: 42.3, IQR: 33, 50, 49 (range: 25-82) N/A 68.1 months 7
HbSβ+, HbSD, HbS/HPFH HR: 1.04; 1.0-1.08) (IQR: 48-78)
Creatinine (μmol/L) (Median: 70, IQR: 59, 85, 
HR: 5.24; 0.41-67.9)
Platelets (HR: 0.99; 0.99-1.0)
LDH (Median: 606, IQR: 385, 879, HR: 0.99;
0.99-1.0)
Hemoglobin (g/L) (Median: 94, IQR: 80, 110, 
HR: 0.62; 0.45-0.86)
HbF (HR: 1.04; 0.9-1.2)
WBC (Median: 9.1, IQR: 7.4, 10.9, 
HR: 0.93; 0.77-1.13)
TRV (≥2.5 m/s: 48/164 {29.27%}, 
HR: 2.71; 0.98-7.5)
Elmariah et al., 201424 542 HbSS, HbSC, HbSβ0, Creatinine (HR: 1.39; 1.25-1.53) 45 (range: 20-86) 58 9.3 years 7
HbSβ+ **Platelets (HR: 1.0; 0.95-1.05) (range: 2.7-10.5)
Use of hydroxyureaa (Yes: 184/441 {41.7%}, 
HR: 0.82; 0.55-1.22)
History of ACS (Yes: 354/475 {74.5%}, 
HR: 1.27; 0.81-1.99)
**Hemoglobin (HR: 1.21; 1.06-1.38)
*Hemoglobin (HR: 1.36; 1.07-1.72)
**WBC (HR: 1.06; 1.0-1.11)
Bilirubin (HR: 1.01; 0.88-1.16)
Log(NT-pro-BNP) (HR: 1.62; 0.66-3.97)
Gladwin et al., 201431 605 HbSS, HbSC Age (Mean: 38.0, SD: 12.57, 40.8 (range: 21.3-65.3) 60.8 2.4 years 8
HR: 1.03; 0.99-1.06) (range: 0.04-3.4)
Creatinine (Mean: 17.07, SD: 35.45, 
HR: 0.99; 0.97-1.01)
Platelets (Mean: 350.63, SD: 134.85, 
HR: 0.99; 0.99-1.0) continued on the next page
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Use of hydroxyurea (Yes: 230/605 {38.02%}, 
HR: 1.62; 0.70-3.73)
History of ACS (Yes: 384/605 {63.47%}, HR: 0.67; 0.29-1.55)
Ferritin (Mean: 607.88, SD: 1297.61, HR: 1.0; 1.0-1.0)
LDH (Mean: 451.82, SD: 298.79, HR: 1.0; 1.0-1.0)
Sex (Male: 278/605 {45.95%} HR: 2.52; 1.03-6.19)
Reticulocyte count (Mean: 8.91, SD: 5.99, HR: 1.03; 0.96-1.1)
Hemoglobin (Mean: 9.31, SD: 1.92, HR: 0.9; 0.71-1.13)
HbF (Mean: 7.30, SD: 7.64, HR: 0.96; 0.9-1.04)
WBC (Mean: 9.68, SD: 3.66, HR: 1.1; 1.0-1.23)
Bilirubin (Mean: 14.66, SD: 31.73, HR: 0.97; 0.93-1.01)
Log(NT-pro-BNP) (Mean: 4.24, SD: 1.56, 
HR: 1.73; 1.41-2.12)
TRV (≥2.5 m/s: 347/562 {61.74%}, HR: 3.5; 1.03-11.9)
Schimmel et al., 201533 85 HbSS, HbSC, HbSβ0, TRV (≥2.5 m/s: 25/81 {30.86%}, 53 (IQR: 37-60) N/A 82 months 7
HbSβ+ HR: 1.1; 0.3-3.7) (IQR: 75-85)
Damy et al., 201630 656 HbSS, HbSβ0 Age (HR: 1.03; 0.99-1.06) N/A N/A 48 months 7
Sex (HR: 1.60; 0.91-2.75) (range: 32-59)
Hemoglobin(g/L) (HR: 1.44; 0.52-3.97)
HbF (HR: 0.97; 0.86-1.10) 
TRV (HR: 3.92; 1.97-7.78)
Karacaoglu et al., 201634 324 HbSS, HbSβ0, HbSβ+ HbF (HR: 0.94; 0.74-1.2) 36.6 ± 13 N/A 66 ± 44 months 7
Hemoglobin (HR: 0.62; 0.45-0.83) (range: 3 – 148 months)
WBC (HR: 1.10; 1.05-1.16)
UNC cohort, 2015 161 HbSS, HbSC, HbSβ0, Age (Mean: 36.83, SD: 12.37, 48.0 49.0 6.4 years 7
HbSβ+, HbSD HR: 1.05; 1.02-1.08) (range: (95% CI: (range: 
Creatinine (Mean: 0.85, SD: 0.52, 29.8-70.2) 44.9-68.6) 0.06-10.3)
HR: 1.67; 1.04-2.67)
Platelets (Mean: 411.45, SD: 156.80, 
HR: 1.0; 0.99-1.01)
Use of hydroxyurea (Yes: 93/161 {57.76%}, 
HR: 0.59; 0.28-1.25)
History of ACS (Yes: 135/161 {83.85%}, 
HR: 1.49; 0.51-4.42)
Ferritin (Mean: 631.76, SD: 813.42, 
HR: 1.0; 1.0-1.0)
LDH (Mean: 984.03, SD: 496.54, 
HR: 1.0; 0.99-1.0)
Gender (Male: 64/161 {39.75%}, 
HR: 0.83; 0.39-1.79)
Reticulocyte count (Mean: 7.38, 
SD: 4.68, HR: 1.1; 1.02-1.18)
Hemoglobin (Mean: 9.15, SD: 1.75, 
HR: 0.72; 0.57-0.9)
HbF (Mean: 8.24, SD: 7.52, HR: 0.95; 0.9-1.0)
WBC (Mean: 9.40, SD: 2.81, HR: 1.1; 0.97-1.27)
Bilirubin (Mean: 2.49, SD: 2.34, HR: 1.06; 0.88-1.27)
Log(NT-proBNP) (Mean: 4.74, SD: 1.09, HR: 1.59; 1.22-2.08)
TRV (≥2.5 m/s): 47/110 {42.73%}, HR: 2.79; 0.88-8.83)
*With Hydroxyurea; ** Without Hydroxyurea; LDH: lactate dehydrogenase; HbF: fetal hemoglobin; HR: hazard ratio; Pain Crisis: frequency of Pain Crisis; TRV: tricuspid regurgitant jet velocity; IQR:
interquartile range; CI: confidence interval. *The paper by Voskariduo et al.21 reports OR for Cox PH model: we have treated them as HRs. Here, reported median is presumed to be the same as the
mean; data have been pooled to obtain overall mean. aOnly HbSS/HbSβ0 thalassemia patients evaluated.
continued from the previous page
ues to confirm the diagnosis. With the strength of data
showing that increased TRV and PHT are associated with
mortality in SCD, we recommend that patients undergo
periodic echocardiographic screening for assessment of
mortality risk, consistent with recently published clinical
practice guidelines.40 NT-pro-BNP levels assess ventricular
strain and levels greater than 160 pg/mL are reported to be
an independent risk factor for mortality in SCD.41,42 The
utility of NT-pro-BNP alone as a screening tool for PHT
has not been studied, although in combination with TRV
and 6-minute walk distance, it appears to increase the pre-
dictive capacity for PHT.10
In the UNC cohort, the effect of all the variables that
were selected in the final model were stronger in the mul-
tivariable model than in the univariable model, without
any change in the direction. D-dimer and the numbers of
pain episodes were not significantly associated with mor-
tality when they were considered individually, but the
effects became significant after controlling for each other,
TRV and genotype. The effect for TRV was statistically
Mortality in sickle cell disease 
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significant in univariable analysis and it became much
stronger in the multivariable model.
This meta-analysis provides additional evidence that
decreased HbF level is associated with increased mortality
in SCD. There is strong epidemiological and clinical evi-
dence that elevated HbF level is associated with relatively
mild clinical manifestations of SCD.7 The reduction of dis-
ease severity by elevated levels of HbF is the basis for the
development of HbF-inducing drugs. The beneficial effect
of hydroxyurea in SCD is thought to be largely due to the
induction of HbF following ‘stress erythropoiesis’,
although the production of nitric oxide and the soluble
guanylyl cyclase and cGMP-dependent protein kinase
pathway may play a role in induced expression of the γ-
globin gene.43 Although no significant association was
observed between the use of hydroxyurea and mortality
in the meta-analysis, there are not sufficient data on
adherence to hydroxyurea or the doses of hydroxyurea in
the individual studies. 
Sickle cell disease has been described as an inflammato-
ry disease.44 While not statistically significant, there was a
trend towards an association between WBC and mortality
in the meta-analysis.  Although leukocytes contribute to
disease pathophysiology,45 it remains uncertain whether a
decrease in the leukocyte count is associated with clinical
benefit.17,19 It has been suggested that the association
P. Maitra et al.
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Figure 4. Forest plots of hazard ratios for variables significantly associated with mortality in random effects meta-analyses (continued on next page). (A) Age (per
10-year increase in age) was significantly associated with mortality [hazard ratio (HR): 1.28; 95% confidence interval (CI): 1.10-1.50]. (B) TRV ≥ 2.5 m/s (HR: 3.03;
95%CI: 2.0-4.60). (C) Reticulocyte count was significantly associated with mortality (HR: 1.05; 95%CI: 1.01-1.10); 
A
B
C
between neutropenia and the frequency of pain episodes
in the Multicenter Study of Hydroxyurea (MSH)17 was
'forced' due to the study design requiring a titration of
hydroxyurea to maximum tolerated dose. This appears to
be supported by the MSH follow-up study, during which
patients received doses of hydroxyurea that were less than
the maximum tolerated doses, with no notable effects on
leukocyte counts.19 In addition to its inflammatory nature,
SCD is characterized by hypercoagulability.46,47 There is
increasing evidence that coagulation activation plays a role
in disease pathophysiology46 and may be associated with
complications of SCD.47,48 Consistent with the hypercoag-
ulable state in SCD, venous thromboembolism is common
and is associated with increased mortality in this patient
population.49 Further studies are required to define the
contribution of coagulation activation to SCD pathogene-
sis as well as its effects on adverse outcomes. 
The present study appears to confirm previous reports of
early death in patients with SCD. It is conceivable that the
current practice of commencing hydroxyurea in young chil-
dren, possibly combined with subsequent decreases in both
morbidity and end-organ damage, may result in greater
longevity of SCD patients.  A prospective, multicenter
study will be required to confirm whether the survival of
SCD patients has improved in the hydroxyurea era.
This study has several limitations. The studies in the
meta-analysis were conducted at referral centers which
usually see only the  more severe cases; the studies  may,
therefore, not be representative of the general SCD popu-
lation. The number of eligible contemporary studies eval-
uating mortality in adult patients with SCD was relatively
small and meta-analyses were not performed for several
clinically important complications such as acute pain
episodes and stroke. Although considerable effort was
made to study unique patient populations, we recognize
that some individual patients may be represented in more
than one cohort or publication. Patients with varied SCD
genotypes were enrolled in the individual studies, with
inadequate data on concomitant alpha thalassemia, and
dosing  and adherence to hydroxyurea. We did not include
studies from Africa and other developing countries due to
our concerns regarding the limited healthcare infrastruc-
ture in many of these countries and the limited use of
hydroxyurea compared with the United States and
Europe. Despite these limitations, this meta-analysis of 9
published studies as well as the UNC cohort represents
the largest number of SCD patients (n=3257) in whom
risk factors for mortality have been evaluated in the
hydroxyurea era. With the increased availability and util-
ity of hydroxyurea, a prospective study to evaluate the
factors associated with mortality in adult patients is war-
ranted. 
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Figure 4. (continued). Forest plots of hazard ratios for variables significantly associated with mortality in random effects meta-analyses. (D) Fetal hemoglobin was
significantly associated with mortality (HR: 0.97; 95% CI: 0.94-1.0). (E) Log(NT-pro-BNP) was significantly associated with mortality (HR: 1.68; 95%CI: 1.48-1.90).
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